Streetbeat News

Analyst Ratings

VRTX

Vertex Pharmaceuticals reported Q3 earnings of $4.08 per share, beating estimates of $3.98. However, sales of $2.48 billion missed estimates of $2.50 billion. The company revised its FY23 sales forecast to $9.85 billion. Following the earnings announcement, several analysts adjusted their price targets for Vertex. The company's shares fell 0.6% to $383.51 on Tuesday.

Portfolio Pulse from Lisa Levin

November 07, 2023 | 6:36 pm

DDOG

Needham analyst Mike Cikos maintains a 'Buy' rating on Datadog (NASDAQ:DDOG) and raises the price target from $110 to $125.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:35 pm

BVH

B. Riley Securities analyst Mike Crawford has downgraded Bluegreen Vacations (NYSE:BVH) from Buy to Neutral, while raising the price target from $66 to $75.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:33 pm

SRAD

Sportradar Group's shares have seen an upward movement in the last 15 minutes. This comes after Baird reiterated its 'Buy' rating and $18 price target for the company.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:31 pm

KIDS

Needham analyst Mike Matson has maintained a 'Buy' rating on OrthoPediatrics (NASDAQ:KIDS) but lowered the price target from $55 to $37.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:30 pm

VVX

RBC Capital analyst Ken Herbert has maintained an 'Outperform' rating on V2X (NYSE:VVX) but lowered the price target from $62 to $55.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:29 pm

SAFE

RBC Capital analyst Kenneth Lee has maintained an Outperform rating on Safehold (NYSE:SAFE) but lowered the price target from $38 to $33.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:27 pm

VRTX

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and lowered the price target from $350 to $347.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:23 pm

OLO

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on Olo (NYSE:OLO) but has lowered the price target from $11 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:21 pm

PRLD

HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Prelude Therapeutics (NASDAQ:PRLD) but lowers the price target from $6 to $5.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:20 pm